ADA: GLP-1 Receptor Agonist Use Beneficial in Adults With Obesity, Autoimmune Disease MONDAY, June 8, 2026 -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
Despite decades of research, effective treatments remain limited
Sinatra reveals his top heart-healthy secrets for losing weight
For most people, this occurs within 2-3 months
Studies that score 15 will be considered low quality, while scores 610 will be considered high quality. The Grading of Recommendations Assessment, Development, and Evaluation Working Group methodology (GRADE) [19] will be used to classify the certainty of evidence
Personal dosing (also known as microdosing) is when you use lower doses than the standard protocols approved by the FDA